Search the GHTC website

Global health R&D delivers for Mississippi

US government investment in global health R&D has delivered

$19.4 million
to Mississippi research institutions
200+ new jobs
for Mississippi
Mississippi's top USG-funded global health R&D institutions

Mississippi's top USG-funded global health R&D institutions

University of Mississippi (including University of Mississippi Medical Center)
$18.1 million
University of Southern Mississippi
$724 thousand
Jackson State University
$269 thousand
Mississippi State University
$202 thousand
Mississippi University for Women
$164 thousand
Mississippi industry in global health R&D

Mississippi industry in global health R&D

ElSohly Laboratories
Location(s): Oxford
Emergent Biosolutions
Location(s): Hattiesburg

Mississippi's top areas of global health R&D by USG funding

Hepatitis C
Neglected tropical diseases
Global health R&D at work in Mississippi

The University of Mississippi School of Pharmacy is working to make a common malaria drug safer. Primaquine is an inexpensive drug that is highly effective against malaria. However, people with a certain enzyme deficiency can have a life-threatening reaction to the drug. This deficiency is common in regions where malaria is found, so many public health programs are reluctant to use primaquine. If the researchers can alter the drug to stop the reaction, it could be used more widely. Malaria infects more than 200 million people each year, killing almost half a million, most of whom are young children.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Claire Suni